Indivior takes a punt on Addex's addiction candidate

3 January 2018

Opioid dependence specialist Indivior (LSE: INDV) has teamed up with a small Swiss company in the hope of developing a new addiction treatment that could provide a benefit for alcoholics and cocaine users.

The company, which is best known as the maker of heroin substitute Suboxone, could pay Addex Therapeutics (SIX: ADXN) $330 in milestone payments if its ADX71441 delivers on the potential that Indivior has identified.

"Modulation of the GABAB receptor pathway is an attractive mechanism, particularly for the potential it holds in advancing treatments for alcohol use disorder and cocaine use disorder"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK